TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097794
Drug: BR1015-1 + BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
Study: NCT06175351
Drug: 9MW1911
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV 9MW1911 every 4 weeks.
Study: NCT06175351
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV placebo every 4 weeks.
Study: NCT05559125
Drug: STSA-1002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05559125
Drug: STSA-1005 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05920408
Drug: EXS21546
Approvals — FDA: no, EMA: no, PMDA: no
Description: EXS21546 Granule in Capsule
Study: NCT04570293
Drug: vehicle plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle patches are identical to the active patch, except for the absence of lidocaine, without any optical differences.For each patient, the painful area and the trigger point will be chosen for treatment. The investigator will instruct the patient to replace the patch every 12 hours. The patches could be applied during the night (application in the evening and removal in the morning), or during the day. Patients will be told to apply up to three patches at one time.
Study: NCT04838704
Drug: Ruxolitinib+Calcineurin +Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose ruxolitinib combine with calcineurin and short course of methotrexate.
Study: NCT04838704
Drug: Calcineurin +Methotrexate+Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: calcineurin and short course of methotrexate and mycophenolate mofetil
Study: NCT04932291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT05623111
Drug: Incobotulinumtoxin-A 100 UNIT Injection
Normalized name: incobotulinumtoxinA 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural injection
Study: NCT05977166
Drug: medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients participated in the current study will receive breathing excesses in form of Diaphragmatic breathing exercise and Pursed lip breathing with traditional medical treatment in form of (vitamin D, vitamin C and Anticoagulation drugs ,group A will receive 60 minutes of HBOT(100%oxygen at 2 ATA with five minutes air breaks every twenty minutes daily in morning for three weeks then take period time of rest about 30 minutes before starting breathing exercise.
Study: NCT04276155
Drug: non-systematic prescription of anticoagulant therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: the prescription of anticoagulant is managed by an implantable device follow up
Study: NCT04512638
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment is the same in all groups.~Monotherapy for 4 weeks with:~No penicillin contra-indication~* Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~After 4 weeks patients will be switched to consolidation antibiotics:~No penicillin contra-indication~* Amoxicillin 1g bid PO Penicillin contra-indication or intolerance~* Clindamycin 300mg tid PO~Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.
Study: NCT05121324
Drug: Standardized seizure protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a standardized seizure protocol for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
Study: NCT05121324
Drug: Conventional seizure protocol
Normalized name: BRACELET,MEDICAL ALERT SEIZURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control is the EMS agency's current seizure protocol, based on conventional calculation-based dosing. These vary from one EMS agency to the other with respect to recommended midazolam doses ranging from 0.05-0.3 mg/kg and with multiple route choices listed, including intravenous, intraosseous, intramuscular, intranasal, and rectal.~for paramedics that prioritizes administration of only intramuscular (IM) or intranasal (IN) midazolam, up to 2 doses given 5 minutes apart, with age-based dosing as follows: 6-16 months (1.25 mg); 17 months-5 years (2.5 mg); 6-11 years (5 mg); 12-13 years (10 mg).
Study: NCT03063190
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive placebo oral tablets
Study: NCT05514249
Drug: CRD-TMH-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive a single dose of CRD-TMH-001 administered via intravenous injection.
Study: NCT05450627
Drug: Pancreatic Enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry of pancreatic enzyme therapy prescribed to included patients
Study: NCT05699070
Drug: DWC202211 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202211 for 5 days~Aspirin 100mg
Study: NCT05699070
Drug: DWC202212 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202212 for 3 days~Rabeprazole 5mg
Study: NCT05699070
Drug: DWC202211 100mg + DWC202212 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg
Study: NCT05042609
Drug: FDA approved steroid eye drop (masked)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved steroid eye drop Dosed four times a day (QID)
Study: NCT06073925
Drug: VIT D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50000 IU per week of VIT D
Study: NCT06184958
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C:placebo group (25 patients) will receive placebo 100 ml normal saline given in 40 minutes with 20 minutes follow up to obverse any delayed complication. This procedure will be repeated weekly for 3 weeks
Study: NCT06423716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given 2 weeks prior to total knee arthroplasty and continued for 6 weeks after surgery.
Study: NCT05293678
Drug: REGN15160 (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in single intravenous (IV) dose
Study: NCT05293678
Drug: Matching Placebo (IV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in single IV dose
Study: NCT05293678
Drug: REGN15160 (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in single subcutaneous (SC) dose
Study: NCT05293678
Drug: Matching Placebo (SC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in single SC dose
Study: NCT04574947
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During induction and maintenance of anaesthesia, 0.9% sodium chloride solution will be injected intravenously at a rate equivalent to lidocaine solution.
Study: NCT05549154
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo was filled with excipients (aniseed ether, refined vegetable oil), and the shape and size were the same as vitamin D2 soft capsule.the control group was given placebo, 5 placebo capsules twice weekly for 6 months of the intervention. The medication was dispensed by a designated person (not the investigator) in advance and independently according to the patient's medication number (only the drug number was provided on the outer packaging).
Study: NCT05608785
Drug: IBI315
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI315 is a recombinant fully humanized anti-programmed death receptor 1 (PD-1) and humanized anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody injection.
Study: NCT05608785
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a type of chemotherapy. It is used as a treatment for different types of cancer, including gastric cancer.
Study: NCT05608785
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT05608785
Drug: Anrotinib
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling.
Study: NCT05493267
Drug: Treatment regimens for MDR-TB
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Study: NCT05525182
Drug: ES16001 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composition: Elaeocarpus extract 40mg tablet
Study: NCT05525182
Drug: ES16001 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaeocarpus extract 80 mg tablet
Study: NCT05525182
Drug: ES16001 160 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elaeocarpus extract 160 mg tablet
Study: NCT05525182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell
Study: NCT04857827
Drug: QLS-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution QD OU dosing for 14 days followed by 14 days BID OU dosing.
Study: NCT05749393
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous heparin was administered during intracranial aneurysm embolization with a guide catheter and discontinued at the end of the procedure.
Study: NCT05233410
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT06256991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a powder with a similar appearance, smell, and taste as patiromer, but without and clinically detectable effects. It is intended for oral intake.
Study: NCT05320393
Drug: PrabotulinumtoxinA-Xvfs
Normalized name: prabotulinumtoxinA-xvfs
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment of 40 units
Study: NCT05320393
Drug: PrabotulinumtoxinA-Xvfs
Normalized name: prabotulinumtoxinA-xvfs
Approvals — FDA: no, EMA: no, PMDA: no
Description: One treatment of 20 units
Study: NCT04835168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04759365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulation for oral capsule
Study: NCT06408116
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy
Study: NCT06538662
Drug: FID 123320 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational sterile aqueous solution
Study: NCT06538662
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: FID 123320 Ophthalmic Solution inactive ingredients
Study: NCT06672536
Drug: SCT520FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT520FF dose level 1，IVI
Study: NCT06672536
Drug: SCT520FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT520FF dose level 2，IVI
Study: NCT06672536
Drug: SCT520FF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT520FF dose level 3，IVI
Study: NCT05660135
Drug: Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olomax Tab 20/5/5mg Olomax Tab 20/5/10mg Olomax Tab 40/5/5mg Olomax Tab 40/5/10mg
Study: NCT00002085
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05559307
Drug: Xingnaojing injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xingnaojing injection 20 ml+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 7 days.
Study: NCT04991480
Drug: ART4215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ART4215 by mouth daily in 21-day cycles.
Study: NCT04957758
Drug: OC-01 (varenicline) nasal spray 1.2 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC-01
Study: NCT04957758
Drug: Placebo (vehicle) nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle)
Study: NCT05680558
Drug: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal Photopheresis (ECP)
Study: NCT05848765
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anthracycline
Study: NCT05926427
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not specified, recommended regimen according to histopathologic type
Study: NCT05848765
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alkylating agent (chemotherapy drug)
Study: NCT05848765
Drug: Investigation agent 2
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed
Study: NCT05848765
Drug: Investigation agent 3
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
Study: NCT00002363
Drug: Peptide Construction 3, Synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05674253
Drug: Dexmedetomidine + Hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive dexmedetomidine 0.7 ɥg/kg/hr IV infusion before aortic cross-clamping, and will be continued intra-operatively and in ICU till weaning from mechanical ventilation Patients also will also receive Hydrocortisone 100 mg intravenous (IV) before aortic cross-clamping then 100 mg every 8 hours after surgery which will be continued for 48 hours
Study: NCT04687423
Drug: FCN-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-011 will be given orally in ascending doses starting at 50 mg Q12h or 100mg QD until the maximum tolerated dose or recommended dose is reached.
Study: NCT04485260
Drug: KRT-232
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered by mouth
Study: NCT05444257
Drug: VX-121/TEZ/D-IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination tablets for oral administration.
Study: NCT06150794
Drug: Methotrexate Injection
Normalized name: methotrexate Injection
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A ring block with 0.5 mL plain lignocaine (2%) will be administered in the web spaces on either side of the digit, followed by a 2.5-mg intramatrical methotrexate injection into each side of the nail at a point 2.5 mm proximal and lateral to the junction of proximal and lateral nail folds.
Study: NCT06104956
Drug: HFNO weaning protocol
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algorithm based on SpO2 values and respiratory rate: a decrease of FiO2 and of the flow will be done
Study: NCT06104956
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weaning methods will be left to the free choice of the practitioner.
Study: NCT04762498
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15 mg oral dose methotrexate administered weekly
Study: NCT06026995
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection with a fixed dose of 12 mg
Study: NCT04512911
Drug: Antiarrhythmic medications
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of anti arrhythmic medication or dose increase
Study: NCT04733963
Drug: Fruquintinib Plus Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with fruquintinib at the dose determined in phase safety lead-in, orally once daily, on d1-21, given every 4 weeks (Q4W); plus capecitabine at the dose 850mg/m2, orally twice daily, d1-7, given every 2 weeks (Q2W); until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
Study: NCT05568550
Drug: Androgen Deprivation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen Deprivation Therapy (either LHRH agonist or LHRH antagonist) as per treating physician choice will be allowed within 3 months prior to randomization. Duration is per institutional standards.
Study: NCT05441956
Drug: TGRX-326
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are given TGRX-326 tablets orally at one of the dose levels as pre-determined.
Study: NCT03033472
Drug: 600 mg Clindamycin orally
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg Clindamycin orally 30 minutes before treatment
Study: NCT03033472
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo 30 minutes before treatment
Study: NCT05682859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT05168995
Drug: BDP/FF NEXThaler® 100/6 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF NEXThaler® 100/6 maintenance treatment: one or two inhalations twice daily (one inhalation in the morning and one inhalation in the evening).~BDP/FF NEXThaler® 100/6 maintenance and reliever treatment (MART)
Study: NCT05536856
Drug: a new effervescent mixture 5-florouracil formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients will apply a new effervescent mixture 5-florouracil formula prepared at faculty of pharmacy (Girls) - Al-Azhar university
Study: NCT05536856
Drug: 5-Fluorouracil plain powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients will apply the 5-florouracil plain powder on the selected patch followed by 3 milliliters of water till complete dissolution of the powder
Study: NCT05518708
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05251038
Drug: 5 Fluorouracil (5FU)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per standard of care
Study: NCT05251038
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per standard of care
Study: NCT05345210
Drug: Vonoprazan Fumarate+Amoxycillin+Clarithromycin 14days (VAC14)
Normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study: NCT05345210
Drug: Vonoprazan Fumarate+Tetracycline+Furazolidone 14days (VTF14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days VA-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 14 days VA-7d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po for 7 days VTF-14d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 14 days VTF-7d:Vonoprazan Fumarate 20mg bid po, Tetracycline 500mg tid po, Furazolidone 100 bid po for 7 days
Study: NCT05345210
Drug: Vonoprazan Fumarate+Tetracycline+Furazolidone 7days (VTF7)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC-14d:Vonoprazan Fumarate 20mg bid po, Amoxycillin 1000mg bid po, Clarithromycin 500mg bid po for 14 days
Study: NCT05562349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule with no active medication - identical to drug capsule
Study: NCT06194500
Drug: [14C]-LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as oral solution.
Study: NCT06194500
Drug: LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06194500
Drug: [14C]-LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as IV infusion.
Study: NCT00967759
Drug: Fenilefrine isolated
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
Study: NCT05693454
Drug: Infiltration with Ropivacain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local wound infiltration at the end of spine surgery with Ropivacain
Study: NCT00771121
Drug: urea/lactic acid
Normalized name: urea/lactic acid/propylene gly TOPICAL SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: new emulsion type
Study: NCT00771121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: only emulsion base
Study: NCT06467526
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (5 mg) for 2 weeks (1 mg/kg/day for one week with gradually taper for another week with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times)
Study: NCT06182267
Drug: L Arginine
Normalized name: ACETYL ARGININE
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: toothpaste
Study: NCT05379959
Drug: placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a placebo capsule that will only contain lactose.
Study: NCT05732883
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04778800
Drug: LM-first line treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given a standard dose of almonertinib 110 mg/day, orally, and the first efficacy evaluation was performed 4 weeks later. If there was no disease progression in two consecutive evaluations, the dose of almonertinib was increased to 165 mg /Day, oral ± radiotherapy (decided by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses; if there is no disease progression in two consecutive assessments, the dose of almonertinib is increased to 220 mg/day, orally ± Radiotherapy treatment (determined by the investigator), continue to evaluate the efficacy every 4 weeks until the patient progresses.